Although when administered alone did not affect the HDAC activity in the livers of normal rats, safranal had the ability to reduce HDAC activity in the livers of HCC group in a non–dose-dependent manner (Figure 3E). Here, HDAC9 is linked to hepatocellular carcinoma.